Oxford Biomedica

Oxford, United Kingdom
Hybrid — also manufactures internal programs
Lentiviral AAV Plasmid DNA
7 confirmed programs · 3 sponsors · Last scored 2026-04-29
76.2
Signal Score
○ FDA Inspections ✓ Clinical Trials (7) ○ SEC Filings ✓ Press (20) ✓ EMA GMP (4) ✓ MHRA GMP (10)

Quick Facts: Oxford Biomedica

Signal Score
76.2/100 (as of 2026-04-29)
Quality Compliance
100.0/100 — No FDA inspection records found for this manufacturer
Headquarters
Oxford, United Kingdom
Website
Modalities
Lentiviral, AAV, Plasmid DNA
Active Programs
7 confirmed from ClinicalTrials.gov across 3 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Oxford Biomedica

Pioneer in lentiviral vector manufacturing.

Signal Score & Pillar Breakdown

Quality Compliance 100.0
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Source: FDA Data Dashboard
No FDA inspection records found for this manufacturer · Quality score requires FDA inspection data
FDA InspectionsNo US records on file
EMA GMP Certificates4 on record
MHRA GMP Certificates10 on record
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations 58.6
7 active programs across 3 sponsors
Modalities: AAV, Plasmid DNA, Lentiviral
6 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
7 active programs across 3 sponsors · Modalities: AAV, Plasmid DNA, Lentiviral · 6 programs in advanced phases (Phase 2/3)
Programs 7
Sponsors3
ModalitiesLentiviral, AAV, Plasmid DNA
7 active programs across 3 sponsors
Modalities: AAV, Plasmid DNA, Lentiviral
6 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT01856439 Long Term Safety and Efficacy Study of ProSavin in Parkinson's Disease PHASE1/PHASE2 Terminated
NCT01301443 Phase I Dose Escalation Safety Study of RetinoStat in... PHASE1 Completed
NCT00627588 Phase I/II Study of the Safety, Efficacy and Dose Evaluation... PHASE1/PHASE2 Completed
NCT00397345 TroVax Renal Immunotherapy Survival Trial PHASE3 Completed
NCT00445523 Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha... PHASE2 Completed
NCT00325507 Safety and Biological Activity of TroVax® Vaccine Given With... PHASE2 Completed
NCT00083941 A Study of TroVax Vaccine Given in Conjunction With IL-2 for... PHASE2 Completed
Source: ClinicalTrials.gov · Retrieved Jul 04, 2026
Financial Stability 75.0
Publicly traded — financial transparency
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Publicly traded — financial transparency
Capacity 58.0
1 manufacturing site: Oxford, UK
Modalities: Lentiviral, AAV, Plasmid DNA
Capacity assessment: 58.0/100
Sites: Oxford, UK
Source: SEC EDGAR, press monitoring, company profiles
1 manufacturing site
StatusAvailable
1 manufacturing site: Oxford, UK
Modalities: Lentiviral, AAV, Plasmid DNA
Capacity assessment: 58.0/100
Sites: Oxford, UK
Recent Press20 articles
1 manufacturing site: Oxford, UK
Modalities: Lentiviral, AAV, Plasmid DNA
Capacity assessment: 58.0/100

Oxford Biomedica FDA 483 Findings 3 observations · 2025-11-19 → 2025-11-19 ?

By subsystem

  • Personnel & Training 1 (33.3%)
  • Other 1 (33.3%)
  • CAPA 1 (33.3%)

By severity

  • 3 — Moderate: 1
  • 2 — Minor: 2
  • Repeat observations: 0

Most severe findings

  • Moderate (3) CAPA 2025-11-19 21 CFR 820.100(a)
    Lack of or inadequate procedures

    "Procedures for corrective and preventive action have not been adequately established."

  • Minor (2) Other 2025-11-19 21 CFR 830.310(b)
    GUDID Information required for unique device identification.

    "The correct unique device identifier (UDI) information regarding device identifier portion of the UDI assigned to the version or model was not provided to the FDA via the Global Unique Device Identification Database (GUDID)."

  • Minor (2) Personnel & Training 2025-11-19 21 CFR 820.25(a)
    Personnel

    "Personnel do not have the necessary training to perform their jobs."

About this data →

Oxford Biomedica EMA GMP Compliance 4 certificates

2024-04
2023-09
2023-09
2020-12
Compliant Non-Compliant
Certificate Site Country Inspection Date Status
2024_HPF_FR_112 Oxford Biomedica (France) S.A.S. France 2024-04-12 COMPLIANT
2024_HPF_FR_026_ND Oxford Biomedica (France) S.A.S. France 2023-09-22 COMPLIANT
2024_HPF_FR_027_ND Oxford Biomedica (France) S.A.S. France 2023-09-22 COMPLIANT
30363/IMP12861/001 OxFord Biomedica (Ireland) Limited Ireland 2020-12-15 NON-COMPLIANT
Source: EMA EudraGMDP · Retrieved Jul 04, 2026

Oxford Biomedica MHRA GMP Compliance 10 certificates

2025-07
2025-07
2025-03
2025-03
2024-07
2024-07
2024-07
2024-07
2019-09
2016-09
Compliant Non-Compliant
Certificate Site City / Postcode Inspection Date Status
UK MIA 17479 Insp GMP/IMP 17479/19229463-0008[H] OXFORD BIOMEDICA (UK) LIMITED OXFORD OX4 2ZY 2025-07-25 COMPLIANT
UK MIA(IMP) 17479 Insp GMP/IMP 17479/19229463-0008[I] OXFORD BIOMEDICA (UK) LIMITED OXFORD OX4 2ZY 2025-07-25 COMPLIANT
UK MIA 17479 Insp GMP/IMP 17479/12357407-0006[H] OXFORD BIOMEDICA (UK) LIMITED OXFORD OX5 1QU 2025-03-07 COMPLIANT
UK MIA(IMP) 17479 Insp GMP/IMP 17479/12357407-0006[I] OXFORD BIOMEDICA (UK) LIMITED OXFORD OX5 1QU 2025-03-07 COMPLIANT
UK MIA 17479 Insp GMP/IMP 17479/12551187-0008[H] OXFORD BIOMEDICA (UK) LIMITED OXFORD OX4 6LT 2024-07-23 COMPLIANT
UK MIA(IMP) 17479 Insp GMP/IMP 17479/12551187-0008[I] OXFORD BIOMEDICA (UK) LIMITED OXFORD OX4 6LT 2024-07-23 COMPLIANT
UK MIA(IMP) 17479 Insp GMP/IMP 17479/285627-0009[I] OXFORD BIOMEDICA (UK) LIMITED OXFORD OX4 6LX 2024-07-23 COMPLIANT
UK MIA 17479 Insp GMP/IMP 17479/285627-0009[H] OXFORD BIOMEDICA (UK) LIMITED OXFORD OX4 6LX 2024-07-23 COMPLIANT
UK MIA(IMP) 21439 Insp IMP 21439/18803335-0003[I] PET RADIOPHARMACY OXFORD (PROX) OXFORD OX3 7LE 2019-09-24 COMPLIANT
UK MIA(IMP) 21439 Insp GMP/IMP 21439/5232980-0001[I] OXFORD BIOMEDICAL RESEARCH CENTRE OXFORD OX3 7LE 2016-09-28 COMPLIANT
Source: MHRA GMDP Database · Retrieved Jul 04, 2026

Recent News 20 articles

general 2026-04-14
Oxford Biomedica unveils fast-track viral vector service to speed gene therapy development - The Globe and Mail
Oxford Biomedica unveils fast-track viral vector service to speed gene therapy development  The Globe and Mail
Source →
general 2026-04-13
Oxford Biomedica Launches Fast-track Viral Vector Manufacturing Service - DirectorsTalk Interviews
Oxford Biomedica Launches Fast-track Viral Vector Manufacturing Service  DirectorsTalk Interviews
Source →
general 2026-04-13
Oxford BioMedica accelerates viral vector development and manufacture - London South East
Oxford BioMedica accelerates viral vector development and manufacture  London South East
Source →
general 2026-04-13
Oxford Biomedica unveils fast-track viral vector service to speed gene therapy development - TipRanks
Oxford Biomedica unveils fast-track viral vector service to speed gene therapy development  TipRanks
Source →
general 2026-04-13
Oxford Biomedica Share News (OXB) - London South East
Oxford Biomedica Share News (OXB)  London South East
Source →
general 2026-03-31
Oxford Biomedica sets date for 2026 AGM as it underscores cell and gene therapy CDMO role - The Globe and Mail
Oxford Biomedica sets date for 2026 AGM as it underscores cell and gene therapy CDMO role  The Globe and Mail
Source →
general 2026-03-30
Oxford Biomedica sets date for 2026 AGM as it underscores cell and gene therapy CDMO role - TipRanks
Oxford Biomedica sets date for 2026 AGM as it underscores cell and gene therapy CDMO role  TipRanks
Source →
general 2026-03-30
Oxford Biomedica’s Capital Markets Day May Spark Revaluation as Innovation Meets Profitability - Bitget
Oxford Biomedica’s Capital Markets Day May Spark Revaluation as Innovation Meets Profitability  Bitget
Source →
general 2026-03-30
Oxford Biomedica’s Capital Markets Day May Spark Revaluation as Innovation Meets Profitability - Bitget
Oxford Biomedica’s Capital Markets Day May Spark Revaluation as Innovation Meets Profitability  Bitget
Source →
financial 2026-03-27
Oxford Biomedica FY 2025 slides: CDMO turns profitable on 33% revenue surge - ca.investing.com
Oxford Biomedica FY 2025 slides: CDMO turns profitable on 33% revenue surge  Investing.com Canada
Source →
general 2026-03-26
Oxford BioMedica shares fall as warns on loss-making first half - London South East
Oxford BioMedica shares fall as warns on loss-making first half  London South East
Source →
financial 2026-03-26
Earnings call transcript: Oxford Biomedica’s H2 2025 results show strong revenue growth - Investing.com
Earnings call transcript: Oxford Biomedica’s H2 2025 results show strong revenue growth  Investing.com
Source →
financial 2026-03-26
Oxford Biomedica H2 Earnings Call Highlights - Yahoo Finance
Oxford Biomedica H2 Earnings Call Highlights  Yahoo Finance
Source →
facility_expansion 2026-03-26
Oxford BioMedica Returns to Profit as U.S. Expansion and Big Pharma Deals Lift Outlook - TipRanks
Oxford BioMedica Returns to Profit as U.S. Expansion and Big Pharma Deals Lift Outlook  TipRanks
Source →
general 2026-03-26
Oxford BioMedica shares fall as warns on loss-making first half - marketscreener.com
Oxford BioMedica shares fall as warns on loss-making first half  marketscreener.com
Source →
financial 2026-03-26
Oxford Biomedica FY 2025 slides: CDMO turns profitable on 33% revenue surge - Investing.com
Oxford Biomedica FY 2025 slides: CDMO turns profitable on 33% revenue surge  Investing.com
Source →
financial 2026-03-26
Oxford Biomedica H2 Earnings Call Highlights - MarketBeat
Oxford Biomedica H2 Earnings Call Highlights  MarketBeat
Source →
financial 2026-03-26
Earnings call transcript: Oxford Biomedica’s H2 2025 results show strong revenue growth - Investing.com
Earnings call transcript: Oxford Biomedica’s H2 2025 results show strong revenue growth  Investing.com
Source →
financial 2026-03-26
Oxford Biomedica FY 2025 slides: CDMO turns profitable on 33% revenue surge By Investing.com - za.investing.com
Oxford Biomedica FY 2025 slides: CDMO turns profitable on 33% revenue surge By Investing.com  za.investing.com
Source →
general 2026-03-23
Oxford Biomedica resumed with a Buy at Jefferies - TipRanks
Oxford Biomedica resumed with a Buy at Jefferies  TipRanks
Source →

Frequently Asked Questions About Oxford Biomedica

Does Oxford Biomedica hold EMA or MHRA GMP certificates?
CDMO Signal tracks 4 EMA and 10 MHRA GMP certificates for Oxford Biomedica.
How many clinical programs is Oxford Biomedica linked to?
Oxford Biomedica is associated with 7 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is Oxford Biomedica's CDMO Signal Score?
Oxford Biomedica has a Signal Score of 76/100, based on quality, operations, financial stability, and capacity data.
Evaluating Oxford Biomedica for a manufacturing program?
Use the free AI matchmaker to compare Oxford Biomedica against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Lentiviral CDMOs → AAV CDMOs → Plasmid DNA CDMOs →

Similar CDMOs

Thermo Fisher Scientific
Plainville, MA · Alachua, FL · Cambridge, MA
Signal Score: 83.1
AAV, Lentiviral, Plasmid DNA, Adenoviral
Andelyn Biosciences
Columbus, OH
Signal Score: 63.0
AAV, Lentiviral, Plasmid DNA
CoJourney Inc.
Ambler, PA (US operations; primary manufacturing in Hangzhou, Zhejiang, China)
Signal Score: 60.0
Plasmid DNA, AAV, Adenoviral, Lentiviral, Retroviral, mRNA, sgRNA, Exosome
3P Biopharmaceuticals (now 3PBIOVIAN)
Pamplona-Noáin, Spain
Biologics (microbial & mammalian), AAV, Adenoviral, Lentiviral, Cell Therapy, Plasmid DNA, Recombinant Proteins, Biosimilars, Fill/Finish (recombinant proteins & viral vectors)
Rose BioSolutions
Rockville, MD
Plasmid DNA, AAV, Lentiviral, Adenoviral, CAR-T, Cell Therapy, Gene Editing, Cell Solutions / Starting Materials